Benjamin G. Cuiffo, Ph.D.

Principal Scientist

 

Dr. Cuiffo joined Biomodels in 2015 after completing his postdoctoral studies at Beth Israel Deaconess Medical Center and Harvard Medical School, where he was an American Cancer Society Fellow. His postdoctoral work centered upon elucidating the molecular mechanisms of tumor metastasis in preclinical in vitro and in vivo models. Ben brings additional expertise in the biology of tumor- initiating (cancer stem cells) and invasive phenotypes, oncogenic signaling pathways, and noncoding RNAs in cancer. He received his Ph.D. in Molecular and Cell Biology from Brandeis University, where he developed novel strategies to target the RAS oncogene in animal models of leukemia. As the Lead Oncology Scientist at Biomodels, Ben’s active collaboration with clients has optimized the utility, efficiency and translational meaningfulness of a broad range of developing small molecules and immunologically-based therapies.

 

Publications by Benjamin G. Cuiffo, Ph.D.:

Pentraxin-3 is a PI3K signaling target that promotes stem cell-like traits in basal-like breast cancers

Silencing FOXP2 in breast cancer cells promotes cancer stem cell traits and metastasis

MSC-regulated microRNAs converge on the transcription factor FOXP2 and promote breast cancer metastasis

Mesenchymal stem cells in tumor development: emerging roles and concepts

Palmitoylation of oncogenic NRAs is essential for leukemogenesis